Selling Biogen As Growth Slows
February 18, 2016
Biogen’s (BIIB) profit’s are now growing around 10%. With the Biotech sector being weak, and cash being king, I will sell BIIB from the Growth Portfolio.
Research Reports
Cutting Costs to Help Grow
December 17, 2015
Biogen (BIIB) is cutting its workforce 11% to make up for slower growth. BIIB is a good value at 11x earnings, but the stock isn’t doing much.
Double Whammy
August 10, 2015
Biogen (BIIB) suffered a double whammy when it lowered guidance and had poor results on its Alzheimer’s drug.
Relax on Biogen
May 11, 2015
People need to take a chill pill and relax on Biogen (BIIB). Give it some time, relax.
Stable Growth With a Catalyst
February 11, 2015
Biogen (BIIB) provides stable earnings growth and BIIB may have another blockbuster coming soon.
Potentially Another Blockbuster
December 22, 2014
Biogen’s (BIIB) new Alzheimer’s drug could be a blockbuster, so I will add it to the Growth Portfolio & Aggressive Growth Portfolio today.